| Literature DB >> 33627926 |
Kleanthi Gourounti1, Antigoni Sarantaki1, Athina Diamanti1, Paraskevi Giaxi1, Katerina Lykeridou1.
Abstract
BACKGROUND: The aim of this study was to develop and assess the psychometric properties of the Electronic Fetal Monitoring Knowledge Scale (EFMKS), a self-report and short instrument measuring knowledge concerning Electronic Fetal Monitoring (EFM). Methods. The EFMKS was developed in a three-phase process by using an integrated mixed-methods approach that included literature reviews, professional focus groups, expert consultations and a psychometric survey evaluation. The psychometric evaluation was conducted by recruiting a sample of 128 professionals (midwives and doctors). Content validity, exploratory factor analysis, discriminant and construct validity, test-retest reliability and internal consistency were explored.Entities:
Keywords: cardiotocography; electronic fetal monitoring; knowledge; life long education; scale
Year: 2020 PMID: 33627926 PMCID: PMC7879430 DOI: 10.5455/aim.2020.28.254-260
Source DB: PubMed Journal: Acta Inform Med ISSN: 0353-8109
Factor structure of the Electronic Fetal Monitoring Knowledge Scale (EFMKS)
| Item/ Item statement | Loading | Communality |
|---|---|---|
| Factor 1 (Eigenvalue = 3.32, variance explained = 33.27%, α = 0.85 | ||
| 3/ Key characteristics of a reactive NST | 0.812 | 0.771 |
| 4/ Definition and attribution of variable decelerations | 0.805 | 0.669 |
| 1/ Range and determinants of FHR baseline | 0.778 | 0.793 |
| 4/ Range and determinants of FHR variability | 0.751 | 0.832 |
| Factor 2 (Eigenvalue = 2.41, variance explained = 24.12%, cumulative variance explained = 57.39%, α = 0.82 | ||
| 10/ Classification of CTG traces from compensatory to abnormal | 0.860 | 0.885 |
| 6/ Definition and management of severe bradycardia | 0.725 | 0.635 |
| 5/ Definition and attribution of late decelerations | 0.712 | 0.680 |
| Factor 3 (Eigenvalue = 1.56, variance explained = 15.6%, cumulative variance explained = 72.99%, α = 0.80 | ||
| 7/ Progressive hypoxia and CTG traces | 0.785 | 0.637 |
| 8/ Identification of risk for neurological defect and ph | 0.749 | 0.629 |
| 5/Apgar score, accelerations and risk of acidosis | 0.745 | 0.769 |
| NST: Non stress test, FHR: Fetal Heart Rate, CTG: Cardiotocography | ||
| Phase I: Establishment of twenty-five item pool | Phase II: Item reduction because of semantic similarity | |
|---|---|---|
| Q1. Define normal range/ determinants of FHR* baseline | Remains | Q1 remains as it not redundant |
| Q2. Define abnormal range/ determinants of FHR tachycardic baseline | Deleted | Q2 is a redundant item with Q1 in terms of meaning |
| Q3. Define abnormal range/ determinants of FHR bradycardic baseline | Deleted | Q3 is a redundant item with Q1 in terms of meaning turned into a sub-response of Q15 |
| Q4. Define normal range/ determinants of FHR variability | Remains | Q4 remains as it not redundant |
| Q5. Define sinusoidal pattern | Deleted | Q5 is a redundant item with Q4 in terms of meaning and turned into a sub-response of Q18 |
| Q6. Define abnormal/decreased variability | Deleted | Q6 is a redundant item with Q4 in terms of meaning |
| Q7. Define abnormal/marked variability | Deleted | Q7 is a redundant item with Q4 in terms of meaning |
| Q8. Define accelerations | Deleted | Q8 is a redundant item with Q9 in terms of meaning |
| Q9. Key characteristics of a reactive NST* | Remains | Q9 remains as it not redundant |
| Q10. Define decelerations | Deleted | Q10 is a redundant item with Q11, Q12, Q13 in terms of meaning |
| Q11. Define and attribute of variable decelerations | Remains | Q11 remains as it not redundant |
| Q12. Define and attribute of late decelerations | Remains | Q12 remains as it not redundant |
| Q13. Define and attribute of early decelerations | Deleted | Q13 is a redundant item with Q11, Q12 in terms of meaning and turned into a sub-response of Q11 and Q12 |
| Q14. Classification of CTG* traces from compensatory to abnormal | Remains | Q14 remains as it not redundant |
| Q15. Definition and management of severe bradycardia in second stage of labor | Remains | Q15 remains as it not redundant |
| Q16. Interpret a fetal scalp-blood sample | Remains | Q16 remains as it not redundant |
| Q17. Differences between metabolic and respiratory acidosis | Deleted | Q17 is a redundant item with Q16, Q19, Q20 in terms of meaning and turned into a sub-response of Q19 |
| Q18. Progressive hypoxia and CTG traces | Remains | Q18 remains as it not redundant |
| Q19. Identification of risk for neurological defect and ph | Remains | Q19 remains as it not redundant |
| Q20. Apgar score, accelerations and risk of acidosis | Remains | Q20 remains as it not redundant |
| Q21. Evaluate the pattern of contractions | Remains | Q21 remains as it not redundant |
| Q22. Differences between CTG and STAN* | Remains | Q22 remains as it not redundant |
| Q23. Operate CTG equipment and application of transducers | Remains | Q23 remains as it not redundant |
| Q24. Application of fetal scalp electrode | Remains | Q24 remains as it not redundant |
| Q25. Advantages and disadvantages of internal and external monitoring | Remains | Q25 remains as it not redundant |
| * Fetal Heart Rate (FHR), Non stress test (NST), Cardiotocography (CTG), ST-Analysis (STAN) | ||